XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Industry Segment and Geographic Area Information
 12 Months Ended
Jan. 01, 2023
Segment Reporting [Abstract]  
Industry Segment Information Industry Segment and Geographic Area Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1.
The principal products and services of the Company’s two operating segments are:
•Discovery & Analytical Solutions. Provides products and services targeted towards the life sciences and applied markets.
•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the Company evaluates the performance of its segments is adjusted operating income, which consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, including primarily restructuring actions.
Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended:
 
January 1,
2023		January 2,
2022		January 3,
2021
 (In thousands)
Revenues
Discovery & Analytical Solutions$1,292,909 $897,718 $596,585 
Diagnostics2,019,727 2,932,738 2,067,728 
Revenue purchase accounting adjustments(814)(2,648)(1,083)
Total revenues$3,311,822 $3,827,808 $2,663,230 
Segment Operating Income
Discovery & Analytical Solutions$503,243 $281,602 $129,174 
Diagnostics781,985 1,432,769 1,010,361 
Corporate(73,431)(77,364)(73,854)
Subtotal reportable segments1,211,797 1,637,007 1,065,681 
Amortization of intangible assets(370,638)(256,569)(160,991)
Purchase accounting adjustments(45,681)(40,993)(6,382)
Acquisition and divestiture-related costs(39,826)(62,760)(4,335)
Restructuring and other(12,953)(18,228)(26,700)
Operating income from continuing operations742,699 1,258,457 867,273 
Interest and other expense, net90,862 54,875 67,201 
Income from continuing operations before income taxes$651,837 $1,203,582 $800,072 

Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended January 1, 2023:
 Depreciation and Amortization ExpenseCapital Expenditures
 January 1,
2023		January 2,
2022		January 3,
2021		January 1,
2023		January 2,
2022		January 3,
2021
 (In thousands)(In thousands)
Discovery & Analytical Solutions$263,698 $94,700 $48,657 $41,532 $27,818 $6,345 
Diagnostics161,394 214,178 149,738 40,671 57,206 55,236 
Corporate1,908 2,565 3,253 3,429 996 2,053 
Continuing operations$427,000 $311,443 $201,648 $85,632 $86,020 $63,634 

 Total Assets
 January 1,
2023		January 2,
2022
 (In thousands)
Discovery & Analytical Solutions$8,330,045 $8,478,292 
Diagnostics3,991,659 4,692,816 
Corporate114,447 129,904 
Current and long-term assets of discontinued operations1,693,704 1,699,542 
Total assets$14,129,855 $15,000,554 
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended January 1, 2023 and net long-lived assets based on physical location as of January 1, 2023 and January 2, 2022:
 Revenue
 January 1,
2023		January 2,
2022		January 3,
2021
 (In thousands)
U.S.$1,546,520 $1,682,294 $921,574 
International:
China476,366 449,588 305,660 
United Kingdom136,017 357,911 323,837 
Other international1,152,919 1,338,015 1,112,159 
Total international1,765,302 2,145,514 1,741,656 
Total revenue$3,311,822 $3,827,808 $2,663,230 
 
 
Net Long-Lived Assets(1)
 January 1,
2023		January 2,
2022
 (In thousands)
U.S.$311,661 $295,397 
International:
Germany147,766 146,633 
China68,072 59,851 
Other international216,235 222,190 
Total international432,073 428,674 
Total net long-lived assets$743,734 $724,071 
(1) Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment, software and other long-term assets.